Search Results

There are 4729 results for: content related to: GLP -1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c- JNK

  1. Glucagon-like peptide analogues for type 2 diabetes mellitus

    Intervention Review

    The Cochrane Library

    Deepson S. Shyangdan, Pamela Royle, Christine Clar, Pawana Sharma, Norman Waugh and Ailsa Snaith

    Published Online : 5 OCT 2011, DOI: 10.1002/14651858.CD006423.pub2

  2. Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 3, March 2011, Pages: 207–220, M. J. Davies, R. Kela and K. Khunti

    Version of Record online : 24 JAN 2011, DOI: 10.1111/j.1463-1326.2010.01330.x

  3. Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators

    BioFactors

    Volume 42, Issue 6, November/December 2016, Pages: 600–611, Juan Decara, Sergio Arrabal, Daniel Beiroa, Patricia Rivera, Antonio Vargas, Antonia Serrano, Francisco Javier Pavón, Joan Ballesteros, Carlos Dieguez, Rubén Nogueiras, Fernando Rodríguez de Fonseca and Juan Suárez

    Version of Record online : 23 MAY 2016, DOI: 10.1002/biof.1295

  4. You have full text access to this OnlineOpen article
    The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents

    Addiction Biology

    Volume 21, Issue 2, March 2016, Pages: 422–437, Daniel Vallöf, Paola Maccioni, Giancarlo Colombo, Minja Mandrapa, Julia Winsa Jörnulf, Emil Egecioglu, Jörgen A. Engel and Elisabet Jerlhag

    Version of Record online : 25 AUG 2015, DOI: 10.1111/adb.12295

  5. Liraglutide: A New Option for the Treatment of Obesity

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 35, Issue 10, October 2015, Pages: 926–934, Wesley A. Nuffer and Jennifer M. Trujillo

    Version of Record online : 24 OCT 2015, DOI: 10.1002/phar.1639

  6. You have full text access to this OnlineOpen article
    Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus

    Diabetic Medicine

    Volume 29, Issue 3, March 2012, Pages: 313–320, M. J. Davies, B. D. Chubb, I. C. Smith and W. J. Valentine

    Version of Record online : 22 FEB 2012, DOI: 10.1111/j.1464-5491.2011.03429.x

  7. Liraglutide: Clinical Pharmacology and Considerations for Therapy

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 9, September 2011, Pages: 896–911, Evan M. Sisson

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.31.9.896

  8. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 1, January 2013, Pages: 42–54, K. Niswender, X. Pi-Sunyer, J. Buse, K. H. Jensen, A. D. Toft, D. Russell-Jones and B. Zinman

    Version of Record online : 9 SEP 2012, DOI: 10.1111/j.1463-1326.2012.01673.x

  9. You have full text access to this OnlineOpen article
    Liraglutide in oral antidiabetic drug combination therapy

    Diabetes, Obesity and Metabolism

    Volume 14, Issue s2, April 2012, Pages: 13–19, A. J. Garber

    Version of Record online : 8 MAR 2012, DOI: 10.1111/j.1463-1326.2012.01574.x

  10. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 1, January 2011, Pages: 75–80, L. Morrow, M. Hompesch, H. Guthrie, D. Chang and D. J. Chatterjee

    Version of Record online : 28 NOV 2010, DOI: 10.1111/j.1463-1326.2010.01322.x

  11. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 7, July 2010, Pages: 604–612, B. W. Bode, M. A. Testa, M. Magwire, P. M. Hale, M. Hammer, L. Blonde, A. Garber and on behalf of the LEAD-3 Study Group

    Version of Record online : 7 JAN 2010, DOI: 10.1111/j.1463-1326.2010.01196.x

  12. Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 3, March 2015, Pages: 285–293, S. E. Kanoski, Z. Y. Ong, S. M. Fortin, E. S. Schlessinger and H. J. Grill

    Version of Record online : 8 JAN 2015, DOI: 10.1111/dom.12423

  13. Treatment With Liraglutide—a Once-Daily GLP-1 Analog—Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug

    The Journal of Clinical Pharmacology

    Volume 51, Issue 12, December 2011, Pages: 1696–1703, Ms Lisbeth V. Jacobsen, Dr Jan Vouis, Dr Charlotte Hindsberger and Dr Milan Zdravkovic

    Version of Record online : 12 MAR 2013, DOI: 10.1177/0091270010389471

  14. Clinical Studies of Liraglutide, a Novel, Once-Daily Human Glucagon-Like Peptide-1 Analog for Improved Management of Type 2 Diabetes Mellitus

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 29, Issue 12P2, December 2009, Pages: 43S–54S, Scott R. Drab

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.29.pt2.43S

  15. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 4, April 2010, Pages: 341–347, K. Kaku, M. F. Rasmussen, P. Clauson and Y. Seino

    Version of Record online : 21 DEC 2009, DOI: 10.1111/j.1463-1326.2009.01194.x

  16. The Pharmacokinetics, Pharmacodynamics, and Tolerability of Liraglutide, a Once-Daily Human GLP-1 Analogue, After Multiple Subcutaneous Administration in Healthy Chinese Male Subjects

    The Journal of Clinical Pharmacology

    Volume 51, Issue 12, December 2011, Pages: 1620–1627, Dr Ji Jiang, Ms Jianyan Zhang, Ms Lisbeth V. Jacobsen and Dr Pei Hu

    Version of Record online : 12 MAR 2013, DOI: 10.1177/0091270010389468

  17. Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment

    The Journal of Clinical Pharmacology

    Volume 52, Issue 12, December 2012, Pages: 1815–1823, Mr Steen H. Ingwersen, Dr Manoj Khurana, Dr Rajanikanth Madabushi, Ms Estelle Watson, Dr Daniël M. Jonker, Ms Tu Duyen Le Thi, Ms Lisbeth V. Jacobsen and Dr Christoffer W. Tornøe

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011430504

  18. You have full text access to this OnlineOpen article
    Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 11, November 2013, Pages: 1040–1048, K. Hermansen, T. A. Bækdal, M. Düring, A. Pietraszek, L. S. Mortensen, H. Jørgensen and A. Flint

    Version of Record online : 11 JUN 2013, DOI: 10.1111/dom.12133

  19. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 3, March 2013, Pages: 204–212, M. Nauck, A. Frid, K. Hermansen, A. B. Thomsen, M. During, N. Shah, T. Tankova, I. Mitha and D. R. Matthews

    Version of Record online : 11 OCT 2012, DOI: 10.1111/dom.12012